Details of Drug-Drug Interaction
| Drug General Information (ID: DDI2BR1X7T) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Pemetrexed | Drug Info | Dyphylline | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antineoplastics | Bronchodilators | |||||||
| Structure | |||||||||
| Mechanism of Pemetrexed-Dyphylline Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Competitive inhibition of renal tubular secretion Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Pemetrexed | Dyphylline | |||||||
| Mechanism | Pemetrexed | Competitive inhibition of renal tubular secretion of pemetrexed | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Renal tubular secretion | ||||||||
| Factor Description | Renal tubular secretion allows selective transfer of substances from the blood around the capillaries into the renal tubules via filtrate. Drug excretion may be reduced when two drugs compete for renal tubular secretion. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN. | ||||||||||||||||||

